No connection

Search Results

NRXS vs TCRX

NRXS
NeurAxis, Inc.
BEARISH
Price
$7.45
Market Cap
$85.7M
Sector
Healthcare
AI Confidence
90%
TCRX
TScan Therapeutics, Inc.
BEARISH
Price
$1.43
Market Cap
$85.9M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
NRXS
--
TCRX
--
Forward P/E
NRXS
-248.33
TCRX
-1.86
P/B Ratio
NRXS
23.35
TCRX
0.66
P/S Ratio
NRXS
24.01
TCRX
8.32
EV/EBITDA
NRXS
-11.04
TCRX
-0.18

Profitability

Gross Margin
NRXS
84.23%
TCRX
0.0%
Operating Margin
NRXS
-177.34%
TCRX
-851.5%
Profit Margin
NRXS
-218.55%
TCRX
0.0%
ROE
NRXS
-285.36%
TCRX
-71.28%
ROA
NRXS
-80.63%
TCRX
-27.88%

Growth

Revenue Growth
NRXS
27.2%
TCRX
286.0%
Earnings Growth
NRXS
--
TCRX
--

Financial Health

Debt/Equity
NRXS
0.13
TCRX
0.76
Current Ratio
NRXS
2.05
TCRX
8.41
Quick Ratio
NRXS
1.85
TCRX
8.15

Dividends

Dividend Yield
NRXS
--
TCRX
--
Payout Ratio
NRXS
0.0%
TCRX
0.0%

AI Verdict

NRXS BEARISH

NRXS exhibits severe fundamental distress, highlighted by a critical Piotroski F-Score of 1/9, indicating a near-total failure of financial health metrics. While the stock has seen a speculative 217% price increase over the last year, this is completely disconnected from its fundamentals, as evidenced by a -218.55% profit margin and an extreme Price-to-Book ratio of 23.35. Despite moderate revenue growth and a strong current ratio, the company is destroying equity at an alarming rate (ROE -285.36%). The current valuation is unsustainable without a massive and immediate pivot to profitability.

Strengths
Strong Gross Margin (84.23%) suggesting high product value
Healthy liquidity with a Current Ratio of 2.05
Low Debt/Equity ratio (0.13) reducing immediate insolvency risk
Risks
Extreme operational losses (Profit Margin -218.55%)
Severe fundamental weakness (Piotroski F-Score 1/9)
Extreme valuation premiums (P/S 24.01, P/B 23.35)
TCRX BEARISH

TCRX exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 0/9, indicating severe financial distress across all measured categories. While the company maintains a strong liquidity position with a Current Ratio of 8.41, this is offset by a catastrophic operating margin of -851.50% and a 5-year price decline of 86.4%. The stock is currently a speculative binary play, where a massive disconnect exists between the fundamental health (extremely poor) and analyst price targets ($6.00).

Strengths
Exceptionally high liquidity (Current Ratio 8.41)
Significant YoY revenue growth of 286%
Recent trend of beating EPS estimates (3/4 last quarters)
Risks
Zero Piotroski F-Score indicating systemic financial weakness
Extreme operational inefficiency (Operating Margin -851.50%)
Negative ROE of -71.28% showing rapid equity erosion

Compare Another Pair

NRXS vs TCRX: Head-to-Head Comparison

This page compares NeurAxis, Inc. (NRXS) and TScan Therapeutics, Inc. (TCRX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile